Literature DB >> 17293018

The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile.

Karen W H Young1, Ian C Munro, Steve L Taylor, Peter Veldkamp, Jaap T van Dissel.   

Abstract

A whey protein concentrate prepared from the milk of cows that have been immunized against Clostridium difficile (C. difficile) and its toxins, toxin A and toxin B, is produced for use as a medical food for the dietary management of patients with C. difficile-associated diarrhea (CDAD) to prevent a relapse of the infection. The safety of anti-C. difficile whey protein concentrate (anti-CD WPC) is supported by analytical data comparing the composition of raw milk from immunized cows versus that from non-immunized cows, and the composition of anti-CD WPC versus that of regular whey protein concentrate. Additionally, a prospective clinical study was conducted in 77 patients with CDAD to demonstrate the safety of consuming anti-CD WPC to prevent relapse of the infection. This study, which included adverse event monitoring, physical examinations, and extensive hematological and biochemical assessments, showed that anti-CD WPC is safe to consume by patients with CDAD. The available analytical and clinical evidence demonstrate that anti-CD WPC is safe for use by individuals with CDAD, under the described conditions of use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293018     DOI: 10.1016/j.yrtph.2006.12.001

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  9 in total

1.  Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses.

Authors:  Sandra C Numan; Peter Veldkamp; Ed J Kuijper; Renate J van den Berg; Jaap T van Dissel
Journal:  Gut       Date:  2007-06       Impact factor: 23.059

2.  New antimicrobial agents for patients with Clostridium difficile infections.

Authors:  John G Bartlett
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

Review 3.  Is There a Role for the Enteral Administration of Serum-Derived Immunoglobulins in Human Gastrointestinal Disease and Pediatric Critical Care Nutrition?

Authors:  Melissa Van Arsdall; Ikram Haque; Yuying Liu; J Marc Rhoads
Journal:  Adv Nutr       Date:  2016-05-16       Impact factor: 8.701

Review 4.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

Review 5.  Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection.

Authors:  Beatrix Förster; Pui Khi Chung; Monique J T Crobach; Ed J Kuijper
Journal:  Front Microbiol       Date:  2018-06-25       Impact factor: 5.640

6.  Concentration of Immunoglobulins in Microfiltration Permeates of Skim Milk: Impact of Transmembrane Pressure and Temperature on the IgG Transmission Using Different Ceramic Membrane Types and Pore Sizes.

Authors:  Hans-Jürgen Heidebrecht; José Toro-Sierra; Ulrich Kulozik
Journal:  Foods       Date:  2018-06-28

7.  Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.

Authors:  Hans-Jürgen Heidebrecht; William J Weiss; Mark Pulse; Anton Lange; Karina Gisch; Heike Kliem; Sacha Mann; Michael W Pfaffl; Ulrich Kulozik; Christoph von Eichel-Streiber
Journal:  Toxins (Basel)       Date:  2019-02-06       Impact factor: 4.546

8.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

9.  Stimulated enrichment of Clostridium difficile specific IgA in mature cow's milk.

Authors:  Christiane Schmautz; Maria Hillreiner; Ines Ballweg; Michael W Pfaffl; Heike Kliem
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.